View Author
protein expression cancer patient factor cisplatin il -3 receptor study sequence resistance imatinib activity hil -3 transporter effect platinum interleukin monkey death rhesu intervention hemopoietic growth murine blood function chapter level yeast response colony region grade analysis marrow gm-csf uptake treatment burger proliferation species rhil -3 accumulation antipsychotic assay kinase production platinum compounds substitution mouse tumor binding oxaliplatin sensitivity result progenitor hslc 22a transport cerevisiae breast compound number doxorubicin interleukin -3 value netherland van leen -3. dorsser strain concentration evolution formation residue differentiation chemotherapy event addition anticancer
10 Most Recent Publications
|
Association between the ROBO1 gene and body mass index in patients using antipsychotics
(Article)
Vehof, J. Al Hadithy, A.F.Y. Bruggeman, R. Burger, H. Snieder, H. Risselada, A.J. Wilffert, B. Cohen, D. Arends, J. Wiersma, D. Mulder, H. |
2011-08-01
|
|
Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication
(Article)
Vehof, J. Risselada, A.J. Cohen, D. Mulder, H. Bruggeman, R. Al Hadithy, A.F.Y. Burger, H. Snieder, H. Wilffert, B. Arends, J. Wunderink, L. Knegtering, H. Wiersma, D. |
2011-07-01
|
|
Teacher ratings of children's behavior problems and functional impairment across gender and ethnicity: Construct equivalence of the strengths and difficulties questionnaire
(Article)
Zwirs, B.W.C. Burger, H. Schulpen, T.W.J. Vermulst, A.A. HiraSing, R.A. Buitelaar, J.K. |
2011-04-01
|
|
Drug transporters and imatinib treatment: Implications for clinical practice
(Article)
Eechoute, K. Sparreboom, A. Burger, H. Franke, R.M. Schiavon, G. Verweij, J. Loos, W.J. Wiemer, E.A.C. Mathijssen, R.H.J. |
2011-02-01
|
|
Drug transporters of platinum-based anticancer agents and their clinical significance
(Article)
Burger, H. Loos, W.J. Eechoute, K. Verweij, J. Mathijssen, R.H.J. Wiemer, E.A.C. |
2011-02-01
|
|
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
(Article)
Jonge, M.J.A. de Slingerland, M. Wiemer, E.A.C. Burger, H. Mathijssen, R.H.J. Kroep, J.R. Hollander, M.A.G. |
2010-11-01
|
|
Phase i and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
(Article)
Konings, I.R.H.M. Jonge, M.J.A. de Burger, H. Gaast, A. van der Beijsterveldt, L.E.C. van Winkler, H. Verweij, J. Yuan, Z. Hellemans, P. Eskens, F.A.L.M. |
2010-09-28
|
|
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
(Article)
Burger, H. Zoumaro-Djayoon, A. Boersma, A.W.M. Helleman, J. Berns, P.M.J.J. Mathijssen, R.H.J. Loos, W.J. Wiemer, E.A.C. |
2010-02-01
|
|
Interaction of imatinib with human organic ion carriers
(Article)
Hu, S. Franke, R.M. Filipski, K.K. Orwick, S.J. Bruijn, E.A. de Baker, S.D. Burger, H. Sparreboom, A. |
2008-05-15
|
|
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
(Article)
Eskens, F.A.L.M. Mom, C.H. Vries, E. de Planting, A.S.Th. Gietema, J.A. Amelsberg, A. Huisman, H. Doorn, L. van Burger, H. Stopfer, P. Verweij, J. |
2008-01-15
|
